Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
CAMPATH vs BEYFORTUS
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Alemtuzumab is a recombinant humanized monoclonal antibody that binds to CD52, a cell surface antigen expressed on B and T lymphocytes, NK cells, monocytes, and macrophages. Binding induces antibody-dependent cell-mediated cytotoxicity and complement-mediated lysis, resulting in prolonged lymphocyte depletion.
BEYFORTUS (nirsevimab) is a recombinant human monoclonal antibody that binds to the prefusion conformation of the respiratory syncytial virus (RSV) F protein, inhibiting viral entry into host cells by blocking the fusion of the viral envelope with the host cell membrane.
Treatment of B-cell chronic lymphocytic leukemia (B-CLL) in patients who have been treated with alkylating agents and who have failed fludarabine therapy,Off-label: Multiple sclerosis (relapsing forms), Conditioning regimen for hematopoietic stem cell transplantation, Prevention of graft-versus-host disease, Treatment of solid organ transplant rejection
Prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in neonates and infants entering their first RSV season, and in children up to 24 months of age who remain vulnerable through their second RSV season.
12 mg/day intravenously over 2 hours, administered for 5 consecutive days (total 60 mg). For patients with relapsed/refractory chronic lymphocytic leukemia (CLL), the recommended dose is 3 mg/day intravenously on day 1, 10 mg/day on day 2, and 30 mg/day on day 3 (dose escalation), followed by 30 mg/day three times per week on alternate days for up to 11 weeks (total cumulative dose up to 640 mg).
Not applicable; BEYFORTUS (nirsevimab) is indicated for prevention of respiratory syncytial virus lower respiratory tract disease in neonates and infants. No adult dose exists.
Terminal half-life approximately 12 days (range 6-21 days) after repeated doses, supporting weekly dosing in CLL.
Terminal elimination half-life is approximately 26.8 days in infants, supporting season-long protection after a single dose.
Metabolism of alemtuzumab is not well defined; as a monoclonal antibody, it is expected to be catabolized into amino acids via general protein degradation pathways.
Nirsevimab is degraded via catabolic pathways into small peptides and amino acids.
Clearance via opsonization and degradation in reticuloendothelial system; negligible renal or biliary excretion (<1% unchanged).
Beyfortus (nirsevimab) is eliminated primarily via catabolism to small peptides and amino acids. No specific data on renal or biliary excretion; expected to undergo proteolytic degradation with minimal renal or fecal elimination of intact drug.
Not extensively characterized; negligible albumin binding due to monoclonal antibody structure.
Protein binding is approximately 99.5%, primarily to albumin.
Approximately 0.2-0.5 L/kg, indicating distribution primarily within vascular and interstitial spaces.
Volume of distribution is approximately 4.5 L in infants (mean Vd ≈ 0.3 L/kg), indicating distribution primarily in plasma and interstitial fluid.
Intravenous only; bioavailability 100% by IV route; no oral or IM formulation.
Bioavailability after intramuscular injection is approximately 70-80% (absolute bioavailability not established; relative to IV data).
No dose adjustment required for creatinine clearance (Cr Cl) ≥10 m L/min. Use with caution in severe renal impairment (Cr Cl <10 m L/min) or end-stage renal disease; no specific dose recommendations available.
No dosage adjustment required for renal impairment; nirsevimab is a monoclonal antibody not renally cleared.
No dose adjustment required for mild to moderate hepatic impairment (Child-Pugh A or B). For severe hepatic impairment (Child-Pugh C), use caution; no specific dose recommendations available, and safety has not been established.
No dosage adjustment required for hepatic impairment; nirsevimab is a monoclonal antibody not hepatically metabolized.
Not approved for use in pediatric patients. Safety and effectiveness in children under 18 years have not been established. No standard dosing guidelines.
Neonates and infants weighing <5 kg: 50 mg intramuscular (IM) single dose; infants weighing ≥5 kg: 100 mg IM single dose. Administer during RSV season.
No dose adjustment required based solely on age. However, elderly patients (≥65 years) may have higher incidence of infusion-related reactions, immunosuppression, and infections; monitor closely. Use same dosing as adults with attention to renal function.
Not indicated for geriatric population; no dosing recommendations available.
WARNING: CYTOPENIAS, INFUSION REACTIONS, AND INFECTIONS. Cytopenias: Serious, including prolonged pancytopenia and autoimmune cytopenias (hemolytic anemia, thrombocytopenia). Infusion reactions: Severe including hypotension, rigors, fever, and dyspnea; premedicate and monitor. Infections: Serious including CMV, EBV, and other opportunistic infections; monitor for reactivation.
No black box warning.
Cytopenias (including autoimmune hemolytic anemia, aplastic anemia), infusion reactions, serious infections (including CMV, EBV, and other opportunistic infections), immunization with live viral vaccines not recommended, thyroid disorders, autoimmune hepatitis, and progressive multifocal leukoencephalopathy (PML).
Hypersensitivity reactions including anaphylaxis have been reported.,Use caution in patients with thrombocytopenia or any coagulation disorder due to risk of bleeding from intramuscular injection.
Patients with active systemic infections, known hypersensitivity to alemtuzumab or any of its components, and HIV-positive patients with CD4+ count < 250 cells/μL (relative).
History of serious hypersensitivity reaction to nirsevimab or any component of the formulation.
No known food interactions. No restriction on dietary intake.
No known food interactions. BEYFORTUS is administered by intramuscular injection and does not interact with dietary components.
Pregnancy category C. First trimester: Anticipated risk of embryolethality and teratogenicity based on animal studies showing fetal loss and malformations. Second and third trimesters: Risk of hematologic toxicity and immunosuppression in the fetus. Alemtuzumab is an Ig G1 monoclonal antibody that crosses the placenta, with increasing transfer as gestation advances.
BEYFORTUS (nirsevimab) is a human monoclonal antibody against respiratory syncytial virus. There are no adequate and well-controlled studies in pregnant women. In animal reproduction studies, no adverse developmental effects were observed in pregnant rabbits or cynomolgus monkeys at doses up to 10 times the human clinical exposure. However, because monoclonal antibodies are transported across the placenta in increasing amounts as pregnancy progresses (especially in the third trimester), potential fetal exposure may occur. Based on limited data, the risk of major birth defects and miscarriage is unknown but expected to be low due to the Ig G1 nature and lack of known teratogenic signal.
Unknown if excreted into human milk. Given the potential for serious adverse reactions in breastfed infants, including immunosuppression, breastfeeding is not recommended. No M/P ratio available.
There are no data on the presence of nirsevimab in human milk, effects on the breastfed infant, or effects on milk production. Nirsevimab is a human monoclonal antibody (Ig G1) and is expected to be excreted into human milk in small amounts due to the high molecular weight and limited transfer via the neonatal Fc receptor. The M/P ratio has not been determined. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for BEYFORTUS and any potential adverse effects on the breastfed infant from the drug or underlying condition.
No dose adjustment guidelines exist for pregnancy. Alemtuzumab has a long half-life (approximately 12 days) and causes prolonged immunosuppression. Use only if potential benefit justifies potential risk. No specific pharmacokinetic data in pregnancy are available.
No dosing adjustments are required for BEYFORTUS during pregnancy. Pregnancy-related physiological changes (e.g., increased plasma volume, altered renal clearance) are not expected to significantly affect the pharmacokinetics of a monoclonal antibody administered intramuscularly, as nirsevimab has a long half-life and is not renally excreted. The standard single dose of 50 mg (for infants <5 kg) or 100 mg (for infants ≥5 kg) is recommended regardless of pregnancy status.
Premedicate with acetaminophen and antihistamine before infusion to reduce infusion reactions. Monitor for cytopenias; growth factor support may be needed. High risk of CMV reactivation; consider prophylaxis. Lymphocyte depletion is prolonged; live vaccines contraindicated for at least 12 months after therapy.
BEYFORTUS (nirsevimab) is a recombinant human monoclonal antibody for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in neonates and infants. It is administered as a single intramuscular injection, typically 50 mg for infants <5 kg and 100 mg for infants ≥5 kg. It is not a treatment for active RSV infection. It does not interfere with live attenuated vaccines; however, administration with other injectable vaccines at different sites is acceptable. Do not administer to infants with a history of severe hypersensitivity to nirsevimab or any excipients. Efficacy has not been established in infants with a history of RSV infection.
You will receive premedication before each infusion to help prevent infusion-related side effects like fever, chills, or rash.,This medication lowers your white blood cell counts significantly, increasing your risk for infections. Report any fever, sore throat, or cough immediately.,You may experience low red blood cell counts (anemia) and low platelet counts, leading to fatigue or easy bruising/bleeding.,Avoid live vaccines (e.g., MMR, flu nasal spray, shingles vaccine) during treatment and for at least 12 months after.,Use effective contraception during and for 6 months after treatment; this drug can harm a fetus.,Do not receive any immunizations without consulting your doctor first.,Report any signs of infusion reaction during the infusion (e.g., chest tightness, shortness of breath, hives) to your healthcare provider immediately.
This vaccine is given as a single shot to prevent serious RSV disease in your infant.,It is not a treatment for active RSV infection; if your infant has RSV symptoms, inform the healthcare provider.,Common side effects include injection site reactions, rash, and fever. Contact your provider if these persist or worsen.,Inform the healthcare provider of any allergic reactions or bleeding disorders before administration.,Your infant can still receive other vaccines as scheduled.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about CAMPATH vs BEYFORTUS, answered by our medical review team.
CAMPATH is a Monoclonal Antibody, Antineoplastic that works by Alemtuzumab is a recombinant humanized monoclonal antibody that binds to CD52, a cell surface antigen expressed on B and T lymphocytes, NK cells, monocytes, and macrophages. Binding induces antibody-dependent cell-mediated cytotoxicity and complement-mediated lysis, resulting in prolonged lymphocyte depletion.. BEYFORTUS is a Monoclonal Antibody for RSV Prophylaxis that works by BEYFORTUS (nirsevimab) is a recombinant human monoclonal antibody that binds to the prefusion conformation of the respiratory syncytial virus (RSV) F protein, inhibiting viral entry into host cells by blocking the fusion of the viral envelope with the host cell membrane.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between CAMPATH and BEYFORTUS depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of CAMPATH is: 12 mg/day intravenously over 2 hours, administered for 5 consecutive days (total 60 mg). For patients with relapsed/refractory chronic lymphocytic leukemia (CLL), the recommended dose is 3 mg/day intravenously on day 1, 10 mg/day on day 2, and 30 mg/day on day 3 (dose escalation), followed by 30 mg/day three times per week on alternate days for up to 11 weeks (total cumulative dose up to 640 mg).. The standard adult dose of BEYFORTUS is: Not applicable; BEYFORTUS (nirsevimab) is indicated for prevention of respiratory syncytial virus lower respiratory tract disease in neonates and infants. No adult dose exists.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between CAMPATH and BEYFORTUS in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. CAMPATH is classified as Category C. Pregnancy category C. First trimester: Anticipated risk of embryolethality and teratogenicity based on animal studies showing fetal loss and malformations. Second and third trimest. BEYFORTUS is classified as Category C. BEYFORTUS (nirsevimab) is a human monoclonal antibody against respiratory syncytial virus. There are no adequate and well-controlled studies in pregnant women. In animal reproducti. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.